First Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)

Simple item page
dc.contributor.authorAyhan, A.
dc.date.accessioned2024-05-20T11:34:17Z
dc.date.available2024-05-20T11:34:17Z
dc.date.issued2023
dc.identifier.eissn1569-8041en_US
dc.identifier.endpageS512en_US
dc.identifier.issn0923-7534en_US
dc.identifier.issueSupplement 2en_US
dc.identifier.startpageS511en_US
dc.identifier.urihttp://hdl.handle.net/11727/12121
dc.identifier.volume34en_US
dc.identifier.wos001087480201088en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.annonc.2023.09.1926en_US
dc.relation.journalANNALS OF ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleFirst Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)en_US
dc.typeconferenceObjecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine